Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
This guide reviews criteria to determine the best cheap dividend ETF, including cost structure, track record, and diversification benefits for investors.
22,535 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Meta Platforms is catching the eye of value-focused investors. This guide breaks down why meta stock could most under...
Two crypto stock heavyweights drop sharply as the Clarity Act targets passive stablecoin yields, threatening Circle’s...
A seasoned investor warns that the global financial system faces a new kind of threat: capital shifts driven by debt,...
Amazon isn’t only about Prime or AWS. An underrated reason to invest Amazon stock is its fast-growing advertising bus...
TD Cowen boosts its Match Group target on better Tinder metrics, while UBS stays cautious. The market tests whether T...
Anthropic’s spacex compute deal expands access to the Colossus supercomputer, boosting Claude capacity while triggeri...
This deep-dive analyzes redwire (rdw) 2026 earnings potential, examining revenue outlook, contracts, and the catalyst...
A veteran venture investor who backed Nvidia in 2016 reveals a third high-conviction call to lift hardware stocks, ty...
When a trusted investment firm unloads a large stake, markets take notice. This article breaks down a real-world exit...
As defense demand accelerates, Anduril Industries partnering with Rocket Lab to tackle hypersonics could reshape fund...
Rocket Lab is expanding by purchasing a competing space systems group for up to $60 million. This article breaks down...